Progenics Pharmaceuticals (PGNX)

Termination.  This Agreement may be terminated by written notice by either Party (the “Non-Debtor Party”) at any time during the Term (a) upon the declaration by a court of competent jurisdiction that the other Party (the “Debtor Party”) is bankrupt and the Debtor Party’s assets are to be liquidated, (b) upon the filing or institution of bankruptcy, liquidation or receivership proceedings (other than reorganization proceedings under Chapter 11 of the United States Bankruptcy Code) with respect to the Debtor Party, (c) upon an assignment of a substantial portion of the assets for the benefit of creditors by the Debtor Party, (d) in the event a receiver or custodian is appointed for the Debtor Party’s business, or (e) if a substantial portion of the Debtor Party’s business is subject to attachment or similar process; provided, however, that in the case of any involuntary bankruptcy proceeding such right to terminate shall become effective only if the proceeding is not dismissed within sixty (60) days after the filing thereof.  To the extent permitted by applicable law, the effect of a termination under this Section 10.5.1 (Termination) shall be as described in Section 10.4.1 (Upon Termination By Progenics) in case of the Debtor Party is Ono, and in Section 10.4.3 (Effect of Termination by Ono for Cause) in the event the Debtor Party is Progenics.